2-hydroxyglutaric acid

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 1586 references associated with 2-hydroxyglutaric acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2-hydroxyglutaric acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-hydroxyglutaric acid

MeSH term MeSH ID Detail
Phenylketonurias D010661 7 associated lipids
Canavan Disease D017825 2 associated lipids
Metabolic Diseases D008659 12 associated lipids
Tyrosinemias D020176 2 associated lipids
Hyperoxaluria D006959 3 associated lipids
Total 5

PubChem Associated disorders and diseases

PubChem Biomolecular Interactions and Pathways

NCBI Entrez Crosslinks

All references with 2-hydroxyglutaric acid

Download all related citations
Per page 10 20 50 100 | Total 448
Authors Title Published Journal PubMed Link
Lucca LE and Hafler DA Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. 2017 J. Clin. Invest. pmid:28319049
Intlekofer AM et al. L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH. 2017 Nat. Chem. Biol. pmid:28263965
Chaturvedi A et al. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. 2017 Leukemia pmid:28232670
Ma S et al. L2hgdh Deficiency Accumulates l-2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration. 2017 Mol. Cell. Biol. pmid:28137912
Chen F et al. Oncometabolites d- and l-2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions. 2017 Chem. Res. Toxicol. pmid:28269980
Tarhonskaya H et al. Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates. 2017 J. Mol. Biol. pmid:28827149
Obayashi H et al. Plasma 2-hydroxyglutarate and hexanoylcarnitine levels are potential biomarkers for skeletal muscle toxicity in male Fischer 344 rats. 2017 J Toxicol Sci pmid:28717097
Amatangelo MD et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. 2017 Blood pmid:28588019
Ansó E et al. The mitochondrial respiratory chain is essential for haematopoietic stem cell function. 2017 Nat. Cell Biol. pmid:28504706
Jiang B et al. IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation. 2017 Cell Rep pmid:28402860
Kim H et al. In-Vivo Proton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists. 2016 Sep-Oct Korean J Radiol pmid:27587950
Choi C et al. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. 2016 J. Clin. Oncol. pmid:28248126
Burr SP et al. Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase Complex Controls HIF1α Stability in Aerobic Conditions. 2016 Cell Metab. pmid:27923773
Tyrakis PA et al. S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. 2016 Nature pmid:27798602
Nadtochiy SM et al. Acidic pH Is a Metabolic Switch for 2-Hydroxyglutarate Generation and Signaling. 2016 J. Biol. Chem. pmid:27510037
Johannessen TA et al. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. 2016 Mol. Cancer Res. pmid:27430238
Kingsbury JM et al. Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability. 2016 Hum. Mol. Genet. pmid:27427385
Jafari-Khouzani K et al. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. 2016 Neuro-oncology pmid:27382115
Fujii T et al. Targeting isocitrate dehydrogenase (IDH) in cancer. 2016 Discov Med pmid:27355333
Ricoult SJ et al. Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1. 2016 Mol. Cell. Biol. pmid:27354064
Teng X et al. Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis. 2016 ACS Chem. Biol. pmid:27333189
Nagashima H et al. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. 2016 Neuro-oncology pmid:27154922
Chaturvedi A et al. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. 2016 Leukemia pmid:27063596
Fiehn O et al. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. 2016 Elife pmid:26943899
Fathi AT et al. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. 2016 Oncologist pmid:26834160
Heo H et al. On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. 2016 PLoS ONE pmid:26820720
Becker-Kettern J et al. Saccharomyces cerevisiae Forms D-2-Hydroxyglutarate and Couples Its Degradation to D-Lactate Formation via a Cytosolic Transhydrogenase. 2016 J. Biol. Chem. pmid:26774271
Flavahan WA et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. 2016 Nature pmid:26700815
de la Fuente MI et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. 2016 Neuro-oncology pmid:26691210
Emir UE et al. Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. 2016 Cancer Res. pmid:26669865
Liesenfeld DB et al. Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial. 2016 Cancer Epidemiol. Biomarkers Prev. pmid:26585118
Andronesi OC et al. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. 2016 Clin. Cancer Res. pmid:26534967
Waitkus MS et al. Isocitrate dehydrogenase mutations in gliomas. 2016 Neuro-oncology pmid:26188014
Wang P et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. 2015 Cell Rep pmid:26686626
Tateishi K et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. 2015 Cancer Cell pmid:26678339
Churchill H et al. Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma. 2015 Int J Clin Exp Pathol pmid:26617922
Li F et al. NADP(+)-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. 2015 Mol. Cell pmid:26585387
Cheng QY et al. Sensitive Determination of Onco-metabolites of D- and L-2-hydroxyglutarate Enantiomers by Chiral Derivatization Combined with Liquid Chromatography/Mass Spectrometry Analysis. 2015 Sci Rep pmid:26458332
Nadtochiy SM et al. Metabolomic profiling of the heart during acute ischemic preconditioning reveals a role for SIRT1 in rapid cardioprotective metabolic adaptation. 2015 J. Mol. Cell. Cardiol. pmid:26388263
Li L et al. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. 2015 PLoS ONE pmid:26368816
Wu F et al. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. 2015 J. Med. Chem. pmid:26280302
Evans B and Griner E Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. 2015 Elife pmid:26231040
Intlekofer AM et al. Hypoxia Induces Production of L-2-Hydroxyglutarate. 2015 Cell Metab. pmid:26212717
Oldham WM et al. Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. 2015 Cell Metab. pmid:26212716
Tai H and Zhang Z A novel compound heterozygous mutation in a Chinese boy with L-2-hydroxyglutaric aciduria: a case study. 2015 BMC Neurol pmid:26208971
Fu X et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. 2015 Cell Metab. pmid:26190651
Hwang VJ et al. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. 2015 Am. J. Physiol. Renal Physiol. pmid:26155843
Macaulay RJ Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. 2015 Cancer Control pmid:26068765
Suijker J et al. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. 2015 Oncotarget pmid:26046462
Izquierdo-Garcia JL et al. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. 2015 Cancer Res. pmid:26045167
Pichumani K et al. Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas. 2015 Anal. Biochem. pmid:25908561
Lombardi G et al. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. 2015 Oncologist pmid:25862748
Pellegatta S et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. 2015 Acta Neuropathol Commun pmid:25849072
Ma S et al. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. 2015 Oncotarget pmid:25825982
Oizel K et al. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. 2015 Cell Death Dis pmid:25811801
Keum YS and Choi BY Isocitrate dehydrogenase mutations: new opportunities for translational research. 2015 BMB Rep pmid:25787993
Shi X et al. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish. 2015 Blood pmid:25778530
Rzem R et al. A mouse model of L-2-hydroxyglutaric aciduria, a disorder of metabolite repair. 2015 PLoS ONE pmid:25763823
Hirata M et al. Mutant IDH is sufficient to initiate enchondromatosis in mice. 2015 Proc. Natl. Acad. Sci. U.S.A. pmid:25730874
Charitou P et al. FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression. 2015 EMBO Rep. pmid:25648147
Chan SM et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. 2015 Nat. Med. pmid:25599133
Fan J et al. Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. 2015 ACS Chem. Biol. pmid:25406093
Reitman ZJ et al. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. 2015 Blood pmid:25398939
Patay Z et al. Successive distinct high-grade gliomas in L-2-hydroxyglutaric aciduria. 2015 J. Inherit. Metab. Dis. pmid:25338511
Wen H et al. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. 2015 J. Neurochem. pmid:25251602
Suijker J et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. 2015 Oncotarget pmid:25895133
Worth AJ et al. Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal Cells. 2015 Chem. Res. Toxicol. pmid:25800467
Deng G et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. 2015 J. Biol. Chem. pmid:25391653
Natsumeda M et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. 2014 Acta Neuropathol Commun pmid:25376594
Chittaranjan S et al. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. 2014 Oncotarget pmid:25277207
Liu Z et al. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. 2014 J. Med. Chem. pmid:25271760
Shim EH et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. 2014 Cancer Discov pmid:25182153
Saha SK et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. 2014 Nature pmid:25043045
Pope WB Intraoperative mass spectrometry of tumor metabolites. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:25028494
Reitman ZJ et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. 2014 J. Biol. Chem. pmid:24986863
Santagata S et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:24982150
Kato Kaneko M et al. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. 2014 Cancer Sci. pmid:24898068
Fathi AT et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. 2014 Oncologist pmid:24760710
Elhammali A et al. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. 2014 Cancer Discov pmid:24740997
Tarhonskaya H et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. 2014 Nat Commun pmid:24594748
Akbay EA et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. 2014 Genes Dev. pmid:24589777
Pusch S et al. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. 2014 Acta Neuropathol Commun pmid:24529257
Menendez JA et al. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. 2014 Cell Cycle pmid:24526120
Borger DR et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. 2014 Clin. Cancer Res. pmid:24478380
Işıkay S et al. A child with L-2 hydroxyglutaric aciduria presenting with dilated cardiomyopathy: coincidence or a new syndrome? 2014 Anadolu Kardiyol Derg pmid:24382499
Terunuma A et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. 2014 J. Clin. Invest. pmid:24316975
Gilbert MR et al. Autophagy and oxidative stress in gliomas with IDH1 mutations. 2014 Acta Neuropathol. pmid:24150401
Navis AC et al. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. 2013 Acta Neuropathol Commun pmid:24252742
Wang JH et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. 2013 Proc. Natl. Acad. Sci. U.S.A. pmid:24082129
Lu C et al. Induction of sarcomas by mutant IDH2. 2013 Genes Dev. pmid:24065766
Chaumeil MM et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. 2013 Nat Commun pmid:24019001
McKenney AS and Levine RL Isocitrate dehydrogenase mutations in leukemia. 2013 J. Clin. Invest. pmid:23999441
Andronesi OC et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. 2013 J. Clin. Invest. pmid:23999439
Guilhamon P et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. 2013 Nat Commun pmid:23863747
Cairns RA and Mak TW Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. 2013 Cancer Discov pmid:23796461
DiNardo CD et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. 2013 Blood pmid:23641016
Losman JA and Kaelin WG What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. 2013 Genes Dev. pmid:23630074
Choi C et al. A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. 2013 NMR Biomed pmid:23592268
Nota B et al. Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. 2013 Am. J. Hum. Genet. pmid:23561848
Pollyea DA et al. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. 2013 Leuk. Lymphoma pmid:22680765